Praveen’s research focus on the discovering novel bimolecular pathways associated with Cardiometabolic diseases (CMDs) using intermediate phenotypes including metabolites, glycans and proteins. Currently Praveen co-lead 1. The metabolome Genetic Architecture Programme (mGAP) focused on the identification of genetic variants (genotyped or imputed using SNP arrays) associated with metabolites measured using non-targetted metabolomics and 2. INTERVAL Flagship project focused on identifying genes and genetic variants associated with ~6,000 biomolecular phenotypes measured through whole exome and whole genome sequencing within the INTERVAL Bioresource. In the past Praveen led various research projects, primarily on cardiovascular diseases (CVDs) and blood pressure (BP) identifying novel biomolecular pathways and mechanisms associated with these complex phenotypes. For example, in 2016, Praveen and colleagues identified 30 new blood pressure- or hypertension-associated genetic regions in a trans-ancestry meta-analyses, including 3 rare missense variants in RBM47, COL21A1 and RRAS with larger effects (>1.5 mm Hg/allele) a low-frequency nonsense variant in ENPEP association with blood pressure regulation in the Renin-Angiotensin-Aldosterone System (RAAS). Praveen currently co-lead the largest genetic study of blood pressure involving ~1.3 million individuals from 92 studies across the globe. In addition to his core research activities, Praveen provide extensive support to CEU’s high performance computing, act as the scientific coordinator of HDR UK Cambridge seminar series and data manager for the CHD Exome+ consortium hosted at the CEU.